Manipal Health Q1 FY27 net profit drops 7.7% to ₹231 crore despite 38% revenue surge
Synopsis
Manipal Health's Q1 FY27 numbers tell two stories at once: a 38% revenue surge and a 7.7% profit drop. The margin squeeze is the price of rapid expansion — Sahyadri integration, new capacity absorption, and a deliberate push into complex specialties. Whether the volume engine converts into sustained bottom-line growth is the question investors will be watching.
Key Takeaways
Manipal Health Enterprises reported a 7.7% YoY fall in consolidated net profit to ₹231 crore in Q1 FY27 .
Revenue jumped 38.1% YoY to ₹3,091 crore , driven by patient-led growth and specialty care.
EBITDA rose 25.6% to ₹736.5 crore ; however, EBITDA margin compressed to 23.8% from 26.2% a year ago.
Inpatient volumes grew 38.8% and occupancy improved 290 basis points to 65% .
Oncology and Orthopedics inpatient revenues surged 62% and 49% respectively under the CONGO-R specialty portfolio.
Re-appointment of Dr Hebri Sudarshan Ballal and Puneet Bhatia as Directors proposed at the 16th AGM .
Manipal Health Enterprises Limited on Thursday posted a 7.7% year-on-year decline in consolidated net profit to ₹231 crore for Q1 FY27, down from ₹250 crore in the same quarter last year. The profit dip came even as the hospital chain delivered one of its strongest revenue quarters, raising questions about margin sustainability as it absorbs recent capacity additions.
Revenue and EBITDA Performance
Revenue surged 38.1% year-on-year to ₹3,091 crore in Q1 FY27, up from ₹2,238 crore in Q1 FY26. EBITDA rose 25.6% to ₹736.5 crore from ₹586.5 crore a year ago. However, the EBITDA margin narrowed to 23.8% from 26.2% in the year-ago period — a compression of 240 basis points — reflecting the cost drag from integrating newly added capacity and the Sahyadri Hospitals network.
Volume Growth and Occupancy
Patient volumes were a clear bright spot. Inpatient volumes grew 38.8% year-on-year, while outpatient volumes climbed 26%. Occupancy improved by 290 basis points year-on-year to 65%, as the expanded network continued to fill newly commissioned beds. Average Revenue Per Occupied Bed (ARPOB), excluding Sahyadri, rose 8.7% year-on-year to ₹77,200 per day, reflecting improved revenue intensity across the existing network.
Specialty Care Driving Growth
High-acuity specialty segments — referred to by the company as CONGO-R specialties — recorded 45% year-on-year growth in gross inpatient revenue, with the specialty mix rising to 65.4%. Oncology and Orthopedics were the standout performers, with inpatient revenues climbing 62% and 49% respectively, supported by broad-based momentum across the portfolio. This comes amid a wider industry trend of Indian hospital chains deliberately shifting their revenue mix toward complex, high-margin procedures.
Sahyadri Integration Progress
Sahyadri Hospitals continued to contribute to network performance, with the hospital business recording 12.8% revenue growth and 18.7% EBITDA growth year-on-year, supported by higher ARPOB and improved operating efficiency. Manipal Health said the integration of Sahyadri is expected to unlock further benefits through greater clinical integration, shared capabilities, and operating scale. Full synergy realisation is anticipated to take several more quarters.
Board and Governance Matters
At its upcoming 16th Annual General Meeting, Manipal Health has proposed the re-appointment of Dr Hebri Sudarshan Ballal as Director, subject to member approval. The company has also proposed the re-appointment of Puneet Bhatia as Director, pending shareholder consent. Both directors are liable to retire by rotation under applicable company law.
With volumes accelerating and specialty revenue mix improving, the key near-term test for Manipal Health will be whether margin recovery can keep pace with its expanding footprint.
Point of View
Paradoxically, a consequence of growth rather than weakness. Rapid capacity addition and the Sahyadri integration are compressing margins in the short term — a pattern seen across India's listed hospital chains when they absorb large acquisitions. The more telling number is the 38% revenue jump and the 65.4% specialty mix: if Manipal can sustain ARPOB momentum and push Sahyadri toward network-level margins, the profit line should recover. The risk is execution drag — integration timelines in Indian healthcare routinely slip, and margin recovery can take longer than management guidance suggests.
NationPress
20 Aug 2026
Frequently Asked Questions
Why did Manipal Health's net profit fall in Q1 FY27?
Manipal Health's consolidated net profit fell 7.7% to ₹231 crore in Q1 FY27, down from ₹250 crore a year ago, primarily due to margin compression from absorbing newly added capacity and ongoing integration costs related to Sahyadri Hospitals. Despite the profit dip, revenue grew strongly at 38.1%.
What was Manipal Health's revenue in Q1 FY27?
Manipal Health reported revenue of ₹3,091 crore in Q1 FY27, a 38.1% increase from ₹2,238 crore in Q1 FY26. The growth was driven by higher inpatient and outpatient volumes, improved occupancy, and rising specialty care revenue.
How did Manipal Health's EBITDA margin change?
The EBITDA margin moderated to 23.8% in Q1 FY27 from 26.2% in Q1 FY26, a compression of around 240 basis points. EBITDA in absolute terms rose 25.6% to ₹736.5 crore, but the margin narrowed due to integration and capacity expansion costs.
Which specialties drove Manipal Health's growth in Q1 FY27?
Oncology and Orthopedics were the top growth drivers, with inpatient revenues rising 62% and 49% respectively. Overall, the CONGO-R specialty portfolio saw 45% year-on-year growth in gross inpatient revenue, with the specialty mix reaching 65.4%.
What is the status of Manipal Health's Sahyadri Hospitals integration?
Sahyadri Hospitals posted 12.8% revenue growth and 18.7% EBITDA growth year-on-year in Q1 FY27. Manipal Health said integration is progressing across clinical and operational functions, with further benefits expected through shared capabilities and operating scale in coming quarters.
